263 related articles for article (PubMed ID: 19286635)
1. Sphingomyelin synthase 2 is one of the determinants for plasma and liver sphingomyelin levels in mice.
Liu J; Zhang H; Li Z; Hailemariam TK; Chakraborty M; Jiang K; Qiu D; Bui HH; Peake DA; Kuo MS; Wadgaonkar R; Cao G; Jiang XC
Arterioscler Thromb Vasc Biol; 2009 Jun; 29(6):850-6. PubMed ID: 19286635
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of sphingomyelin synthase (SMS) affects intracellular sphingomyelin accumulation and plasma membrane lipid organization.
Li Z; Hailemariam TK; Zhou H; Li Y; Duckworth DC; Peake DA; Zhang Y; Kuo MS; Cao G; Jiang XC
Biochim Biophys Acta; 2007 Sep; 1771(9):1186-94. PubMed ID: 17616479
[TBL] [Abstract][Full Text] [Related]
3. Adenovirus-mediated sphingomyelin synthase 2 increases atherosclerotic lesions in ApoE KO mice.
Wang X; Dong J; Zhao Y; Li Y; Wu M
Lipids Health Dis; 2011 Jan; 10():7. PubMed ID: 21235823
[TBL] [Abstract][Full Text] [Related]
4. Adenovirus-mediated overexpression of sphingomyelin synthases 1 and 2 increases the atherogenic potential in mice.
Dong J; Liu J; Lou B; Li Z; Ye X; Wu M; Jiang XC
J Lipid Res; 2006 Jun; 47(6):1307-14. PubMed ID: 16508036
[TBL] [Abstract][Full Text] [Related]
5. Selective reduction in the sphingomyelin content of atherogenic lipoproteins inhibits their retention in murine aortas and the subsequent development of atherosclerosis.
Fan Y; Shi F; Liu J; Dong J; Bui HH; Peake DA; Kuo MS; Cao G; Jiang XC
Arterioscler Thromb Vasc Biol; 2010 Nov; 30(11):2114-20. PubMed ID: 20814016
[TBL] [Abstract][Full Text] [Related]
6. [Sphingomyelin synthase 2 deficiency decreases atherosclerosis and inhibits inflammation in mice].
Qin R; Chen ML; Zhu K; Deng JB; Shi YY
Sheng Li Xue Bao; 2010 Aug; 62(4):333-8. PubMed ID: 20717634
[TBL] [Abstract][Full Text] [Related]
7. Macrophage sphingomyelin synthase 2 deficiency decreases atherosclerosis in mice.
Liu J; Huan C; Chakraborty M; Zhang H; Lu D; Kuo MS; Cao G; Jiang XC
Circ Res; 2009 Jul; 105(3):295-303. PubMed ID: 19590047
[TBL] [Abstract][Full Text] [Related]
8. Effect of liver total sphingomyelin synthase deficiency on plasma lipid metabolism.
Li Z; Chiang YP; He M; Zhang K; Zheng J; Wu W; Cai J; Chen Y; Chen G; Chen Y; Dong J; Worgall TS; Jiang XC
Biochim Biophys Acta Mol Cell Biol Lipids; 2021 May; 1866(5):158898. PubMed ID: 33545384
[TBL] [Abstract][Full Text] [Related]
9. Dynamic modification of sphingomyelin in lipid microdomains controls development of obesity, fatty liver, and type 2 diabetes.
Mitsutake S; Zama K; Yokota H; Yoshida T; Tanaka M; Mitsui M; Ikawa M; Okabe M; Tanaka Y; Yamashita T; Takemoto H; Okazaki T; Watanabe K; Igarashi Y
J Biol Chem; 2011 Aug; 286(32):28544-55. PubMed ID: 21669879
[TBL] [Abstract][Full Text] [Related]
10. Sphingomyelin synthase 2 activity and liver steatosis: an effect of ceramide-mediated peroxisome proliferator-activated receptor γ2 suppression.
Li Y; Dong J; Ding T; Kuo MS; Cao G; Jiang XC; Li Z
Arterioscler Thromb Vasc Biol; 2013 Jul; 33(7):1513-20. PubMed ID: 23640498
[TBL] [Abstract][Full Text] [Related]
11. SMS overexpression and knockdown: impact on cellular sphingomyelin and diacylglycerol metabolism, and cell apoptosis.
Ding T; Li Z; Hailemariam T; Mukherjee S; Maxfield FR; Wu MP; Jiang XC
J Lipid Res; 2008 Feb; 49(2):376-85. PubMed ID: 17982138
[TBL] [Abstract][Full Text] [Related]
12. Both sphingomyelin synthases SMS1 and SMS2 are required for sphingomyelin homeostasis and growth in human HeLa cells.
Tafesse FG; Huitema K; Hermansson M; van der Poel S; van den Dikkenberg J; Uphoff A; Somerharju P; Holthuis JC
J Biol Chem; 2007 Jun; 282(24):17537-47. PubMed ID: 17449912
[TBL] [Abstract][Full Text] [Related]
13. Effect of Total SMS Activity on LDL Catabolism in Mice.
Li Z; He M; Chen G; Souaiaia T; Worgall TS; Jiang XC
Arterioscler Thromb Vasc Biol; 2023 Jul; 43(7):1251-1261. PubMed ID: 37128925
[TBL] [Abstract][Full Text] [Related]
14. All members in the sphingomyelin synthase gene family have ceramide phosphoethanolamine synthase activity.
Ding T; Kabir I; Li Y; Lou C; Yazdanyar A; Xu J; Dong J; Zhou H; Park T; Boutjdir M; Li Z; Jiang XC
J Lipid Res; 2015 Mar; 56(3):537-545. PubMed ID: 25605874
[TBL] [Abstract][Full Text] [Related]
15. Sphingomyelin synthase SMS2 displays dual activity as ceramide phosphoethanolamine synthase.
Ternes P; Brouwers JF; van den Dikkenberg J; Holthuis JC
J Lipid Res; 2009 Nov; 50(11):2270-7. PubMed ID: 19454763
[TBL] [Abstract][Full Text] [Related]
16. Deficiency of sphingomyelin synthase 1 but not sphingomyelin synthase 2 reduces bone formation due to impaired osteoblast differentiation.
Matsumoto G; Hashizume C; Watanabe K; Taniguchi M; Okazaki T
Mol Med; 2019 Dec; 25(1):56. PubMed ID: 31847800
[TBL] [Abstract][Full Text] [Related]
17. Sphingomyelin synthase 2 deficiency attenuates NFkappaB activation.
Hailemariam TK; Huan C; Liu J; Li Z; Roman C; Kalbfeisch M; Bui HH; Peake DA; Kuo MS; Cao G; Wadgaonkar R; Jiang XC
Arterioscler Thromb Vasc Biol; 2008 Aug; 28(8):1519-26. PubMed ID: 18566297
[TBL] [Abstract][Full Text] [Related]
18. Sphingomyelin synthase 2 over-expression induces expression of aortic inflammatory biomarkers and decreases circulating EPCs in ApoE KO mice.
Zhao YR; Dong JB; Li Y; Wu MP
Life Sci; 2012 Jun; 90(21-22):867-73. PubMed ID: 22538014
[TBL] [Abstract][Full Text] [Related]
19. Characterization of the role of sphingomyelin synthase 2 in glucose metabolism in whole-body and peripheral tissues in mice.
Sugimoto M; Shimizu Y; Zhao S; Ukon N; Nishijima K; Wakabayashi M; Yoshioka T; Higashino K; Numata Y; Okuda T; Tamaki N; Hanamatsu H; Igarashi Y; Kuge Y
Biochim Biophys Acta; 2016 Aug; 1861(8 Pt A):688-702. PubMed ID: 27151272
[TBL] [Abstract][Full Text] [Related]
20. Discovery, synthesis and anti-atherosclerotic activities of a novel selective sphingomyelin synthase 2 inhibitor.
Li Y; Huang T; Lou B; Ye D; Qi X; Li X; Hu S; Ding T; Chen Y; Cao Y; Mo M; Dong J; Wei M; Chu Y; Li H; Jiang XC; Cheng N; Zhou L
Eur J Med Chem; 2019 Feb; 163():864-882. PubMed ID: 30580239
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
